title: [Assessment of a pharmaceutical interventional programme in patients on medications with renal risk].
abstract: OBJECTIVE
  To compare the adaptation of medical prescriptions according to the dosage guides in patients with renal disease, before and after applying a pharmaceutical intervention programme. The secondary objectives were to prepare a guide to dosing in renal disease and to measure the prevalence of prescription of drugs with renal risk.
  
  
  METHODS
  Non-randomised, experimental interventional study (before/after) conducted in a general hospital with 800 beds, including hospitalised patients, over the age of 18, with kidney disease and drugs with renal risk prescribed in their pharmacotherapeutic profile. The study was designed to be carried out in two descriptive cross-cutting phases (control group) and a prospective interventional cohort study (intervention group). The primary variable was the percentage non-adaptation according to the stage of renal disease.
  
  
  RESULTS
  The study included 185 patients, 88 in the control group and 97 in the intervention group. In the intervention group, the prevalence of non-compliance before and after the intervention was 18.7 % and 2.1 %, representing a statistically significant reduction in non-adaptation of the dose. The costs saved with the pharmaceutical intervention programme were 1,939.63 euro over two months, the average saving per medication intervened amounting to 62.57 euro (CI 95 %, 23.99-101.14 euro; p = 0.02).
  
  
  CONCLUSIONS
  The results of the study indicate that the application of a pharmaceutical care model based on the prospective validation of drugs with renal risk, very significantly improved the adaptation of dosing regimens in kidney disease.
authors.affiliation: Servicio de Farmacia, Hospital General Universitario de Alicante, Alicante, España. lauraalvarez6@yahoo.es
authors.forename: L
authors.initials: L
authors.lastname: Alvarez Arroyo
authors.forename: E
authors.initials: E
authors.lastname: Climent Grana
authors.forename: N
authors.initials: N
authors.lastname: Bosacoma Ros
authors.forename: S
authors.initials: S
authors.lastname: Roca Meroño
authors.forename: M
authors.initials: M
authors.lastname: Perdiguero Gil
authors.forename: J P
authors.initials: JP
authors.lastname: Ordovás Baines
authors.forename: J
authors.initials: J
authors.lastname: Sánchez Payá
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects; D015897:Comorbidity; D017046:Cost Savings / Q000706:statistics & numerical data; D003430:Cross-Sectional Studies; D016527:Drug Costs; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007674:Kidney Diseases / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000139:chemically induced* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance / Q000706:statistics & numerical data; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D011446:Prospective Studies
chemical_list: D000900:Anti-Bacterial Agents; D004364:Pharmaceutical Preparations